Afternoon D & C Dedicated To Mumbai
Home > Business > 'Committed to serve India patients with best in class technologies'

'Committed to serve India patients with best in class technologies'

Friday, June 30, 2017

Riyaz Desai, MD, MicroPort Scientific Corporation, India

Riyaz Desai is the Managing Director of MicroPort Scientific India P Ltd. He is responsible for MicroPort’s launch, expansion and growth in the region. He has completed more than 22 years in the healthcare industry and played various senior leadership roles in big multinationals and Fortune 500 companies. Desai has vast experience in Leadership Development, Sales and Marketing and corporate planning. He has played pivotal role in business turnarounds, driving profitable growth, building world class teams & managing distribution in Medical devices. In conversation with Dominic Rebello, Riyaz says, “We see this as a new beginning in the Indian healthcare space. Indian government is committed to not only providing universal health coverage but focused on delivering equitable high quality healthcare to all the classes. MicroPort is well poised in aligning with Government of India in this mission.”  

Tell us a few words about yourself and your company?
The Indian arm MicroPort Scientific India Pvt. Ltd., a wholly owned subsidiary of MicroPort Scientific Corporation, is aimed to serve the Indian patients with high-quality and yet affordable medical solutions to save, reshape and improve quality of their life. Making its Indian debut in early 2017 with its flagship 3rd generation Target Eluting Stent called FIREHAWK, MicroPort has made tremendous progress in a very short time in the Indian market in terms of acceptance and early successes in approvals from leading hospitals across the country.

I head the operations in India as MD and am responsible for driving MicroPort’s expansion and growth in the region. I have completed more than 22 years in healthcare industry and have played various senior leadership roles in big multinationals and fortune 500 companies with vast experience in Leadership Development, Sales and Marketing and corporate planning.

What is the latest innovation in stent technology?
Old-generation DES were made of metal and durable  polymer which carried the drug. After 90-100 days the drug is gone but polymer stays there and number of clinical studies has shown that leftover polymer can have a catastrophic effect on patients on longer term. Our innovative TES- Target Eluting Stent technology product Firehawk has proved to be a major success in patients with coronary diseases. It features cutting edge tech such as ultra micro 3D printing and abluminal groove filled design. Target Eluting Stent technology allows Firehawk to achieve the same clinical efficacy as other market leading Drug Eluting Stent with only 1/2 dosage of the drug. Our 3rd generation stent, Firehawk has polymer which gets absorbed in nine months and therefore stent is properly endothelialized  in the artery.

Why are doctors all over the world and India going for FIREHAWK?
FireHawk is witnessing sincere acknowledgement after the innumerable successful clinical trials across the world. Studies undertaken on Firehawk, our Target Eluting Stents (TES) suggest the healing time is lesser than other Drug Eluting Stents (DES).  Firehawk is a Rapamycin Target Eluting Coronary Stent which achieves the same clinical efficacy as other market leading Drug Eluting Stent with only 1/2 dosage of the drug. Additionally, as we use absorbable polymer and henceno residue is left from the stent after the drug has been absorbed by the vessels. This leads to less chances of re-blockage and stent related blood clot formation (thrombosis) as seen in series of large  TARGET clinical trials.”

What are the after effects of price regulation of stents by NPPA in February this year?
We are completely aligned with government of India in its mission of providing affordable healthcare. Now that the government has capped the price, many companies are in a fix whether to continue to sell their third generation stents or not. The government is forcing them while we are voluntarily going to the market and offering our best in class technology at the regulated pricing. “We are 100% committed to serve India patients with best in class technologies”

Where do you see yourself five years down the road?
MicroPort is just not a cardiovascular devices company; we have great product portfolios in various therapeutic areas like orthopedic, neurovascular, peripheral vascular and electrophysiology.

We want to make sure that these technologies are available for Indian patients. We are bringing our next product portfolio in orthopedic soon. In the coming years, we will keep on bringing new technologies across all domains: interventional cardiology, orthopedics, endovascular, neurovascular, electrophysiology, diabetes & endocrine management, surgical management, and others. We are here to serve patients and though there are challenges but constantly we are thinking about how we can make technologies accessible to patients and make an impact in their lives.

No Comments Posted
What is the CAT position of performing intercours
Dr. Rajan B. Bhonsle, M.D. (Bom)
Consulting Sex Therapist & Counsellor
Dr. (Mrs.) Minnu R. Bhonsle, Ph.D.
Consulting Psychotherapist & Counsellor
Select Sun sign:
Aries (Mar 21 - Apr 20)
Aries (Mar 21 - Apr 20)A favorable opportunity in the form of a job or business proposal is likely. At work you will accomplish a difficult task. This will win you the appreciation of your employer or senior and improve your image in your organization. You can look forward to financial benefits soon. Home and family life is peaceful and happy.
- Advertising -
We love our beauty products… But, we also love cu
Who doesn’t like sipping on elaichi chai, especia
Tired of soggy notebooks and leaking makeup this
Read More